Quote | Pandion Therapeutics Inc. (NASDAQ:PAND)
Last: | $60.05 |
---|---|
Change Percent: | 0.22% |
Open: | $59.95 |
Close: | $60.05 |
High: | $60.05 |
Low: | $59.95 |
Volume: | 238,830 |
Last Trade Date Time: | 03/31/2021 04:57:24 pm |
News | Pandion Therapeutics Inc. (NASDAQ:PAND)
Harpoon Therapeutics is a platform immunotherapy company using its TriTAC technology to develop more stable bispecifics to treat cancer. The company has several catalysts for its pipeline of four clinical assets this year that can validate the TriTAC platform. Ultimately, Harpoon ...
Merger activity increased last week. Six multi-billion-dollar deals announced. SPAC frenzy hits a new record. For further details see: Merger Arbitrage Mondays: SPAC IPOs Set A New Record
Message Board Posts | Pandion Therapeutics Inc. (NASDAQ:PAND)
Subject | By | Source | When |
---|---|---|---|
PAND for value right now. Presentation next Thursday. | herbied47 | investorshub | 09/24/2020 8:45:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Pandion Therapeutics Inc. Company Name:
PAND Stock Symbol:
NASDAQ Market:
Best Biotech Stocks To Buy [Or Sell] Right Now Investors looking for high returns could turn to biotech stocks . These stocks are more volatile than your usual pick. However, could this be the right time to buy biotech stocks after rising Treasury yields continue to spark a tech...
Merck (NYSE: MRK) and Pandion Therapeutics, Inc. (NASDAQ: PAND) have reported entry into a definitive agreement where Merck will acquire Pandion for USD 60 per share in cash or a total equity value of USD 1.85 Billion. “This acquisition builds upon Merck...
Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreem...